NEXGEL (NXGL) Investor presentation summary

Strategic transformation and partnerships

• Completed acquisition of regenerative biomaterial assets from Celularity, focusing on tendon repair, skin grafts, and bone growth within the regenerative biomaterials market.

• Established BioNx Surgical as a surgeon-centric commercialization engine and gateway to an integrated life sciences platform.

• Formed a strategic partnership with Fountainhead LifeSciences, securing a $6.5M investment, two board seats, and access to advanced R&D and manufacturing capabilities.

• Fountainhead brings 35 cleared 510(k)s, 21 issued patents, and 20+ products in development, enhancing innovation and market reach.

Integrated platform and commercialization strategy

• BioNx Surgical serves as the unified commercial interface, driving surgeon engagement, education, and demand creation.

• The platform integrates manufacturing, training, R&D, and commercialization, offering a full continuum of care solutions.

• Focus on controlling the value chain from insight and validation to manufacturing and commercialization.

• Commercial team provides access to over 500 approved hospital accounts, supporting rapid market penetration.

Product portfolio and growth strategy

• Expanding product lineup in wound care, surgical, and ocular segments, with new launches scheduled through 2027.

• Consumer products division includes advanced hydrogel wound dressings and skin care solutions.

• Four-stage growth strategy: foundation, integration, expansion, and platform maturity, aiming for national presence.

• Targeting over $250M in revenue by building a scalable, surgeon-centered life sciences platform.